Supplementary Figure 1. Comparison of the Kaplan-Meier survival curves for no anticoagulation (NA) and nafamostat mesylate (NM) groups across different departments and treatment durations. (A–C) Survival analysis for patients in the medical department. (D–F) Survival analysis for patients in the surgical department. (A, D) Overall hospital stay survival analysis. (B, E) Intensive care unit (ICU) stay survival analysis. (C, F) Continuous kidney replacement therapy (CKRT) duration survival analysis. *p < 0.05, statistically significant.